Robert Nelsen was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
Name: Robert Nelsen
Organisation: Arch Venture Partners
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
LSIPR 50, Robert Nelsen, Arch Venture Partners, investment, Alnylam Pharmaceuticals, Juno Therapeutics, Vir Biotechnology, Sage Therapeutics, Illumina
